+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06289348

Psychological Impact of Announcing Phenylketonuria Detected by Newborn Screening Experiences of Parents and Medical Teams in France

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-06-24

80

Participants Needed

1

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

This research investigates the psychological effects on parents and medical teams upon the announcement of phenylketonuria PKU, a rare and serious inherited metabolic disease detected through systematic newborn screening in France. The study aims to better understand these impacts to improve the diagnosis announcement process and the support provided to families and healthcare providers. PKU screening has been routine since 1970, allowing early treatment to prevent neurological damage, but the announcement is often distressing due to its timing and delivery. Participants include parents of children screened for PKU and healthcare professionals involved in the diagnosis process. The study collects data through socio-psychological questionnaires administered to parents shortly after the diagnosis announcement and at follow-up times, alongside structured interviews with a subset of parents, doctors, and midwives. These assessments explore the emotional and psychological responses to the diagnosis announcement, using tools like the revised event impact scale and the Stern interview. During the study, parents complete questionnaires 7 days and 4.5 months after the announcement, and some participate in interviews at 1 month and 4.5 months. Doctors and midwives also undergo interviews to share their experiences and awareness of PKU. Researchers analyze qualitative interview data and quantitative questionnaire results to evaluate anxiety and psychological impact over time. The study spans multiple years, concluding in 2027, with the goal of enhancing communication and support strategies in newborn screening programs.

CONDITIONS

Brief Title

Announcement of Rare Metabolic Diseases in Systematic Newborn Screening: the Phenylketonuria Experience.

Research Team

P

Pascale DELONLAY, MD, PhD

A

Aminata TRAORE

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here